NEOS
$0.62
Neos Therapeutics
($.02)
(2.70%)
NEOS
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $0.00
Revenue:  N/A
Monday
Nov 9
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when NEOS reports earnings?
Beat
Meet
Miss

Where is NEOS's stock price going from here?
Up
Flat
Down
Stock chart of NEOS
Analysts
Summary of analysts' recommendations for NEOS
Score
Grade
Pivots
Resistance
$0.74
$0.72
$0.68

$0.65

Support
$0.61
$0.59
$0.55
Tweet
Growth
Description
Neos Therapeutics, Inc. is engaged in developing, manufacturing and commercializing products for the treatment of attention deficit hyperactivity disorder using drug delivery technologies. Its product candidates include NT-0102 methylphenidate XR orally disintegrating tablet for the treatment of ADHD; NT-0202 amphetamine XR orally disintegrating tablet for the treatment of ADHD; NT-0201 amphetamine XR liquid suspension for the treatment of ADHD and Generic Tussionex, which are in different clinical development stage. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.